This week, the House of Representatives passed the Medicare Part B Improvement Act, a bipartisan bill that, among other provisions, seeks to amend title XVIII of the Social Security Act in order to address the delivery of at-home infusion therapy.
This week, the House of Representatives passed the Medicare Part B Improvement Act, a bipartisan bill that, among other provisions, seeks to amend title XVIII of the Social Security Act in order to address the delivery of at-home infusion therapy.
The bill provides for the addition of a temporary home infusion benefit to Medicare, beginning in 2019 and ending in 2021, payment for which would be based on the physician fee schedule. The bill also provides for the following:
The Congressional Budget Office (CBO) estimated that the act would reduce direct spending by $4 million over the 2018 to 2027 period, and would not affect revenues.
Home infusion trade organizations such as the National Home Infusion Association (NHIA) have publicly supported the act—NHIA’s chairman, Varner Richards, PharmD, provided testimony in support of the bill to the Committee on Energy and Commerce last week—and hope that the Senate will follow the House’s lead.
Many clinicians, however, may prove resistant to the idea of administering infused biologics and biosimilars in home settings. The American College of Rheumatology (ACR)’s official position statement, “Patient Safety and Site of Service for Biologics,” says that, because adverse events are not uncommon—and are potentially severe—with infused biologics, such infusions should be administered in a monitored healthcare setting. ACR’s position goes on to say that infusion should be supervised by a provider with appropriate training, nurse practitioners and physician assistants who supervise infusion centers should work with physicians, and no patient should be forced to receive infusions at home for the purpose of lowering healthcare costs.
Despite the act’s move to encourage home infusion for Medicare patients, CMS has simultaneously proposed a cut to reimbursement to home healthcare agencies (HHAs) in the Medicare program. In the agency’s 2018 Home Health Prospective Payment System Rate Update, CMS proposes a cut of 0.4% (an estimated $80 million) in payments to HHAs. Modern Healthcare reports that most of the cuts proposed were initially provided for in the Affordable Care Act (ACA) in order to address overpayments for home health services, and that payments to HHAs have seen cuts of $260 million in 2016, $60 million in 2015, and $200 million in 2014. These cuts appear to have prompted more than 900 home health providers to drop from the Medicare rolls in the past 3 years.
CMS also proposes to reimburse for home healthcare in 30-day periods beginning in 2019; currently, Medicare pays for home health services for 60-day periods, which may be renewed if the patient’s physician deems further care necessary.
CMS will receive comments on its proposed changes to home health payments until September 25, 2017.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.